NASDAQ:AXGN AxoGen - AXGN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $9.22 +0.16 (+1.77%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$9.13▼$9.4250-Day Range$7.53▼$10.9552-Week Range$6.87▼$13.66Volume160,778 shsAverage Volume251,025 shsMarket Capitalization$392.77 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media AxoGen MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside84.4% Upside$17.00 Price TargetShort InterestBearish3.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.70Based on 3 Articles This WeekInsider TradingSelling Shares$344,052 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.78) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 starsMedical Sector631st out of 995 stocksElectromedical Equipment Industry12th out of 24 stocks 3.5 Analyst's Opinion Consensus RatingAxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, AxoGen has a forecasted upside of 84.4% from its current price of $9.22.Amount of Analyst CoverageAxoGen has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.37% of the float of AxoGen has been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in AxoGen has recently increased by 19.30%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AXGN. Previous Next 2.6 News and Social Media Coverage News SentimentAxoGen has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for AxoGen this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added AxoGen to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $344,052.00 in company stock.Percentage Held by InsidersOnly 7.51% of the stock of AxoGen is held by insiders.Percentage Held by Institutions76.22% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.78) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -13.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -13.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 3.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AxoGen (NASDAQ:AXGN) StockAxogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.Read More Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address AXGN Stock News HeadlinesMarch 19, 2023 | americanbankingnews.comAxoGen (NASDAQ:AXGN) Earns "Market Outperform" Rating from JMP SecuritiesMarch 17, 2023 | finance.yahoo.comAxoGen, Inc. (NASDAQ:AXGN) Q4 2022 Earnings Call TranscriptMarch 28, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 17, 2023 | americanbankingnews.comAxoGen (NASDAQ:AXGN) Now Covered by Analysts at StockNews.comMarch 17, 2023 | americanbankingnews.comFY2023 EPS Estimates for AxoGen, Inc. (NASDAQ:AXGN) Lowered by Jefferies Financial GroupMarch 17, 2023 | americanbankingnews.comAxoGen, Inc. (NASDAQ:AXGN) Forecasted to Earn FY2023 Earnings of ($0.66) Per ShareMarch 16, 2023 | finance.yahoo.comAxoGen Full Year 2022 Earnings: EPS Beats ExpectationsMarch 14, 2023 | finance.yahoo.comAxogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial ResultsMarch 28, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 10, 2023 | finance.yahoo.comAxogen, Inc. Appoints Marc Began as Executive Vice President and General CounselMarch 6, 2023 | finance.yahoo.comAxogen, Inc. Appoints Marc Began as Executive Vice President and General CounselMarch 2, 2023 | finance.yahoo.comAxogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023March 1, 2023 | finance.yahoo.comAxoGen (NASDAQ:AXGN) investors are sitting on a loss of 76% if they invested five years agoFebruary 13, 2023 | finance.yahoo.comAxogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing OfficerJanuary 9, 2023 | finance.yahoo.comAxogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022January 5, 2023 | finance.yahoo.comAxogen Announces Independent Publication of Comparative Nerve Gap Repair Meta-Analysis of 35 peer-reviewed studies of Allograft, Autograft, and ConduitsJanuary 4, 2023 | finance.yahoo.comAxogen to Participate at J.P. Morgan 41st Annual Healthcare ConferenceJanuary 1, 2023 | finance.yahoo.comAxoGen, Inc. (NASDAQ:AXGN) is favoured by institutional owners who hold 65% of the companyDecember 19, 2022 | finance.yahoo.comAxogen Patient to Ride the 2023 Donate Life Rose Parade® Float Supporting awareness of organ and tissue donationDecember 10, 2022 | seekingalpha.comAxoGen: Rally Looks To Be Exhausted, Revise To HoldNovember 11, 2022 | finance.yahoo.comHere's Why "Trend" Investors Would Love Betting on AxoGen (AXGN)October 31, 2022 | finance.yahoo.comAxogen, Inc. announces the appointment of Adrian Tyndall, M.D. MPH, FACEP to its Board of Directors and the retirement of founding Director Mark Gold, M.D.October 27, 2022 | finance.yahoo.comAxoGen (AXGN) Upgraded to Buy: Here's What You Should KnowOctober 20, 2022 | globenewswire.comAxogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022 - GlobeNewswireOctober 20, 2022 | finance.yahoo.comAxogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022October 19, 2022 | nasdaq.comAre Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year? - NasdaqOctober 19, 2022 | finance.yahoo.comAre Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address AXGN Company Calendar Last Earnings11/02/2021Today3/27/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXGN CUSIPN/A CIK805928 Webwww.axogeninc.com Phone(386) 462-6800Fax386-462-6801Employees428Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+84.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,950,000.00 Net Margins-20.88% Pretax Margin-20.89% Return on Equity-19.05% Return on Assets-9.90% Debt Debt-to-Equity Ratio0.65 Current Ratio4.13 Quick Ratio3.33 Sales & Book Value Annual Sales$138.58 million Price / Sales2.84 Cash FlowN/A Price / Cash FlowN/A Book Value$2.39 per share Price / Book3.86Miscellaneous Outstanding Shares42,600,000Free Float39,403,000Market Cap$393.20 million OptionableOptionable Beta0.54 Key ExecutivesKaren L. ZaderejChairman, President & Chief Executive OfficerMike DonovanVice President-OperationsPeter J. MarianiChief Financial Officer & Executive Vice PresidentErick Wayne DeVinneyVice President-Clinical & Translational SciencesIvica DucicMedical DirectorKey CompetitorsEdap TmsNASDAQ:EDAPZynexNASDAQ:ZYXIViewRayNASDAQ:VRAYFONARNASDAQ:FONRHyperfineNASDAQ:HYPRView All CompetitorsInsiders & InstitutionsVoya Investment Management LLCSold 7,651 shares on 2/28/2023Ownership: 0.063%Legal & General Group PlcSold 6,196 shares on 2/15/2023Ownership: 0.247%Susquehanna Fundamental Investments LLCBought 3,221 shares on 2/15/2023Ownership: 0.058%Squarepoint Ops LLCBought 4,192 shares on 2/15/2023Ownership: 0.044%Gamco Investors INC. ET ALSold 5,000 shares on 2/15/2023Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions AXGN Stock - Frequently Asked Questions Should I buy or sell AxoGen stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXGN shares. View AXGN analyst ratings or view top-rated stocks. What is AxoGen's stock price forecast for 2023? 4 equities research analysts have issued twelve-month price objectives for AxoGen's shares. Their AXGN share price forecasts range from $15.00 to $20.00. On average, they expect the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 84.2% from the stock's current price. View analysts price targets for AXGN or view top-rated stocks among Wall Street analysts. How have AXGN shares performed in 2023? AxoGen's stock was trading at $9.98 at the start of the year. Since then, AXGN shares have decreased by 7.5% and is now trading at $9.23. View the best growth stocks for 2023 here. Are investors shorting AxoGen? AxoGen saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,360,000 shares, an increase of 19.3% from the February 28th total of 1,140,000 shares. Based on an average daily trading volume, of 238,400 shares, the days-to-cover ratio is presently 5.7 days. Approximately 3.4% of the shares of the company are short sold. View AxoGen's Short Interest. When is AxoGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our AXGN earnings forecast. How were AxoGen's earnings last quarter? AxoGen, Inc. (NASDAQ:AXGN) released its earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.05. The medical equipment provider earned $31.20 million during the quarter, compared to analysts' expectations of $34.65 million. AxoGen had a negative trailing twelve-month return on equity of 19.05% and a negative net margin of 20.88%. During the same period in the previous year, the company posted ($0.04) EPS. What ETFs hold AxoGen's stock? ETFs with the largest weight of AxoGen (NASDAQ:AXGN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Equipment ETF (XHE), IQ Chaikin U.S. Small Cap ETF (CSML) and iShares U.S. Medical Devices ETF (IHI) and What guidance has AxoGen issued on next quarter's earnings? AxoGen updated its FY 2023 earnings guidance on Tuesday, March, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $154.00 million-$159.00 million, compared to the consensus revenue estimate of $158.94 million. What is Karen Zaderej's approval rating as AxoGen's CEO? 19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL). What is AxoGen's stock symbol? AxoGen trades on the NASDAQ under the ticker symbol "AXGN." Who are AxoGen's major shareholders? AxoGen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (8.39%), First Light Asset Management LLC (5.61%), Bank of America Corp DE (4.30%), Point72 Asset Management L.P. (4.29%), William Blair Investment Management LLC (3.47%) and Soleus Capital Management L.P. (1.79%). Insiders that own company stock include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan and Peter J Mariani. View institutional ownership trends. How do I buy shares of AxoGen? Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AxoGen's stock price today? One share of AXGN stock can currently be purchased for approximately $9.23. How much money does AxoGen make? AxoGen (NASDAQ:AXGN) has a market capitalization of $393.20 million and generates $138.58 million in revenue each year. The medical equipment provider earns $-28,950,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. How many employees does AxoGen have? The company employs 428 workers across the globe. How can I contact AxoGen? AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The official website for the company is www.axogeninc.com. The medical equipment provider can be reached via phone at (386) 462-6800, via email at investorrelations@axogeninc.com, or via fax at 386-462-6801. This page (NASDAQ:AXGN) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.